LEADER 05282nam 2200493 450 001 9910678097703321 005 20231110215109.0 010 $a1-119-78341-0 010 $a1-119-78343-7 010 $a1-119-78342-9 035 $a(MiAaPQ)EBC6983460 035 $a(Au-PeEL)EBL6983460 035 $a(CKB)22249455400041 035 $a(OCoLC)1287742247 035 $a(EXLCZ)9922249455400041 100 $a20221201d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCarbon monoxide in drug discovery $ebasics, pharmacology, and therapeutic potential /$fedited by Leo E. Otterbein, Binghe Wang 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons, Inc.,$d[2022] 210 4$dİ2022 215 $a1 online resource (1005 pages) 225 1 $aWiley Series in Drug Discovery and Development 300 $aIncludes index. 311 08$aPrint version: Wang, Binghe Carbon Monoxide in Drug Discovery Newark : John Wiley & Sons, Incorporated,c2022 9781119783404 327 $aIntro -- Carbon Monoxide in Drug Discovery -- Contents -- List of Contributors -- Preface: Carbon Monoxide: Promises and Challenges in Its Pharmaceutical Development -- Section I General Background and Physiological Actions -- 1 Endogenous CO Production in Sickness and in Health -- 2 Molecular Mechanisms of Actions for CO: An Overview -- 3 Pharmacokinetic Characteristics of Carbon Monoxide -- 4 Carbon Monoxide and Energy Metabolism -- 5 Role of CO in Circadian Clock -- 6 Carbon Monoxide and Mitochondria -- 7 Carbon Monoxide, Oxygen, and Pseudohypoxia -- 8 Nitric Oxide in Human Physiology: Production, Regulation, and Interaction with Carbon Monoxide Signaling -- 9 When Carbon Monoxide Meets Hydrogen Sulfide -- 10 Biliverdin and Bilirubin as Parallel Products of CO Formation: Not Just Bystanders -- Section II Delivery Forms -- 11 Delivery Systems and Noncarrier Formulations -- 12 Metal-Based Carbon Monoxide-Releasing Molecules (CO-RMs) as Pharmacologically Active Therapeutics -- 13 Organic CO Donors that Rely on Photolysis for CO Release -- 14 Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions -- 15 Targeted Delivery of Carbon Monoxide -- 16 Anesthesia-Related Carbon Monoxide Exposure -- 17 Natural Products that Generate Carbon Monoxide: Chemistry and Nutritional Implications -- Section III Carbon Monoxide Sensing and Scavenging -- 18 Fluorescent Probes for Intracellular Carbon Monoxide Detection -- Section IV Therapeutic Applications -- 19 CO in Solid Organ Transplantation -- 20 Carbon Monoxide in Lung Injury and Disease -- 21 Carbon Monoxide in Acute Brain Injury and Brain Protection -- 22 CO as a Protective Mediator of Liver Injury: The Role of PERK in HO-1/CO-Mediated Maintenance of Cellular Homeostasis in the Liver -- 23 CO and Cancer -- 24 CO and Diabetes -- 25 Carbon Monoxide and Acute Kidney Injury. 327 $a26 CO as an Antiplatelet Agent: An Energy Metabolism Perspective -- 27 CO in Gastrointestinal Physiology and Protection -- 28 Carbon Monoxide and Sickle Cell Disease -- 29 CO and Pain Management -- 30 Clinical Trials of Low-Dose Carbon Monoxide -- Index -- EULA. 330 $a"Carbon monoxide, one of the smallest organic natural molecules, is widely known for its toxicity. Formation of CO via incomplete combustion is a major contributing factor to accidental or intentional CO poisoning, leading to severe health consequences or death. In addition, CO is a by-product of tobacco smoking, and has been associated with some of the harmful effects of smoking. However, less known and probably far more important is the recognition of the essential physiological roles of CO as a signaling molecule in mammals. Against over more than a century of negative connotation, the last few decades have proven that CO possesses a multitude of physiological roles and therapeutic functions including regulation of the immune response, cellular proliferation, and control of cell survival. This concept is supported by the discovery that CO is produced by all cells and more so under conditions of stress. This book comprehensively summarizes key aspects of CO's endogenous roles, therapeutic functions, and challenges that we face in its development as a therapeutic agent. We hope this preface will provide a thread for reading this book and a birds-eye view of the landscape for understanding this field, and more importantly lay out the challenges ahead in understanding the detailed mechanisms of action of CO and in its development as a therapeutic agent. We have divided the book into four sections that provide a framework for the reader to follow the evolution of CO from an accepted poison to a bioactive molecule that may offer enormous clinical benefits"--$cProvided by publisher. 410 0$aWiley Series in Drug Discovery and Development 606 $aDrugs$xResearch 615 0$aDrugs$xResearch. 676 $a615.1072 702 $aWang$b Binghe$f1962- 702 $aOtterbein$b Leo E. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910678097703321 996 $aCarbon monoxide in drug discovery$93068664 997 $aUNINA